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Psychotic experiences are common in the general population, and predict later psychotic
illness. Much less is known about negative symptoms in the general population.
Method
This study utilized a sample of 4,914 Israel-born individuals aged 25–34 years who were
screened for psychopathology in the 1980's. Though not designed to specifically assess
negative symptoms, data were available on 9 self-report items representing avolition and so-
cial withdrawal, and on 5 interviewer-rated items assessing speech deficits, flat affect and
poor hygiene. Psychotic experiences were assessed using the False Beliefs and Percep-
tions subscale of the Psychiatric Epidemiology Research Interview. Psychiatric hospitaliza-
tion was ascertained 24 years later using a nation-wide psychiatric hospitalization registry.
Results
After removing subjects with diagnosable psychotic disorders at baseline, 20.2% had at
least one negative symptom. Negative symptoms were associated with increased risk of later
schizophrenia only in the presence of strong (frequent) psychotic experiences (OR = 13.0,
9%CI: 2.1–79.4).
Conclusions
Negative symptoms are common in the general population, though the majority of people
with negative symptoms do not manifest a clinically diagnosed psychiatric disorder.
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Negative symptoms and psychotic experiences critically depend on each other’s co-occur-
rence in increasing risk for later schizophrenia.
Introduction
Numerous studies and meta-analyses have shown that attenuated forms of positive symptoms
(psychotic experiences) are not uncommon in the general population [1], and predict later psy-
chotic illness [2–6]. Much less is known about the prevalence of negative symptoms in the pop-
ulation, including poverty of thought and speech, impoverished emotional experience,
diminished affect, decreased motivation toward goal-directed behavior, and decreased social
drive [7]. The only population-based report on negative symptoms in the general population is
a recent longitudinal study by Dominguez and colleagues[8], that found that 15.7% of adoles-
cents and young adults reported lifetime cumulative incidence of negative/disorganized symp-
toms alone, and 5.5% reported both positive and negative symptoms. Negative symptoms were
predictive of positive symptoms over time, and particularly the co-occurrence of positive and
negative symptoms was associated with increased probability of functional impairment and
help-seeking behavior [8]. However, the association between negative symptoms and hospitali-
zation for schizophrenia has not yet been examined in a population-based sample.
Given the prevalence and functional impact of negative symptoms, it is important to further
our knowledge on the prevalence of such symptoms in the general population, and their associ-
ation with later mental disorders. This study aimed to examine the prevalence of negative
symptoms in the general population and their association with psychotic experiences and with
later hospitalization for schizophrenia, utilizing data from a population-based cohort of indi-
viduals assessed as young adults, and then followed for 24 years.
Methods
The association between negative symptoms and subsequent psychiatric hospitalization was ex-
amined by merging data from an epidemiological study conducted in Israel in the 1980's with
data from the National Psychiatric Hospitalization Case Registry. After receiving approval from
the IRB at the Sheba Medical Center, these databases were linked in 2007 using the national
identification number (analogous to the US Social Security number) as the linking variable. For
subjects who participated in the epidemiological study and appeared in the hospitalization regis-
try, dates of hospitalizations and discharge diagnoses were added to the file. Individuals who
had a discharge diagnosis of schizophrenia (ICD-10 F20.0-F20.9) at any hospitalization were
considered as clinically diagnosed with schizophrenia.
To preserve subjects' confidentiality, the national identification number was removed before
the linked file was transferred to the investigators. Hence, patient records were anonymized
and de-identified prior to analysis.
Epidemiological Study
This study utilized data from a two-stage epidemiological study of mental disorders among
young adults in a 10-year birth cohort (1949–1958) conducted in Israel in the 1980's [9,10]. As
part of the original study’s goal to compare the risk of selected disorders in socio-economically
contrasting ethnic groups, a sample of 19,000 Israel-born individuals was drawn from the popu-
lation registry and screened for father’s continent of origin (North Africa or Europe) and level of
education. This was done to balance socioeconomic status within advantaged and disadvantaged
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ethnic groups by over-sampling disadvantaged subjects from North African origin with high ed-
ucational level and advantaged subjects of European origin with low educational level. Based on
gender, education, ethnicity, and year of birth, 5,200 subjects were selected.
This cohort-based sample was screened and diagnosed for psychotic and other psychiatric
disorders in two stages. During the screening stage, 94.5% (n = 4,914) were interviewed using a
Hebrew version of the Psychiatric Epidemiology Research Interview (PERI), a well validated
screening tool [11–13]. Data were not obtained for 5.5% subjects (n = 286). Mean age at the
time of the interview was 29.4 years (SD = 3.1 years); 49.6% were men. The PERI interview also
included self-report of lifetime use of cannabis (including single or rare usage), coded 0 = no,
1 = yes.
Subjects reaching predetermined cut-off values on the PERI screening stage [13], unable to
complete the screening interview, or suspected of having a history of psychiatric illness, were
referred for a clinical diagnostic (second) stage (n = 2,643). In addition, to determine the rates
of false negatives, 18.3% of the 2271 screened negatives—who did not reach the predetermined
cut-off values on the PERI—were randomly selected and also referred for a diagnostic interview
[10]. From this sub-sample, 2,741 (90.8%) persons were interviewed by psychiatrists using a
modified lifetime version of the Schedule for Affective Disorders and Schizophrenia (SADS-I; I
for Israel) to arrive at a Research Diagnostic Criteria (RDC) [14] diagnosis. The SADS-I also in-
cluded an assessment of the best level of social functioning during the five years preceding the
interview, rated on a scale of 1 (superior) to 7 (grossly inadequate). Mean time from the screen-
ing stage (PERI) to the second stage (SADS-I) was 1.1 years ±11.5 months (range 0–4.5 years).
Assessment of Negative Symptoms
Two of the study researchers (MW and NW) reviewed the symptoms covered in the PERI and
identified items assessing negative symptoms similar to those assessed in the Positive and Neg-
ative Syndrome Scale (PANSS) [15] and the Scale for the Assessment of Negative Symptoms
(SANS) [16], scales commonly used for the assessment of negative symptoms. Fourteen symp-
toms (9 self-reported and 5 interviewer-rated; see S1 Table) were identified. The self-report
items were scored on a 5-point Likert scale, ranging from (0) “never” to (4) “very often” or “not
at all like you” (0) to “very much like you” (4), whereas the interviewer-rated items were scored
“present” or absent”.
The fourteen negative symptoms were included in a principal component analysis with vari-
max rotation. Four symptom clusters were extracted in this analysis: avolition (4 items), social
withdrawal (5 items), speech deficits (2 items), flat affect and poor hygiene (3 items) (Table 1).
As flat affect and poor hygiene are two distinct concepts, this cluster was split into two: flat af-
fect (2 items) and poor hygiene (1 item).
Assessment of Psychotic Experiences
Self-reports of psychotic experiences were assessed using the 13-item False Beliefs and Percep-
tions sub-scale of the PERI. Subjects were asked whether they had experienced psychotic experi-
ences and the frequency of each symptom during the past year was recorded on a 5-item Likert
scale rated (0) “never”, (1) “rarely”, (2) “sometimes”, (3) “often”, and (4) “very often”. As in
previous studies, including one using this sample [5,6,17,18], separate scores were defined for
“weak” (occurring rarely or sometimes) and “strong” (occurring often or very often) psychotic
experiences. The scale includes questions assessing core positive symptoms such as delusions,
hallucinations, bizarre thinking; feeling possessed; feeling dissolved; feeling that thoughts were
not one's own; and beliefs of mind control. An example of a typical question is: “have you felt
that your mind was dominated by external forces that you had no control over?” The PERI-False
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Beliefs and Perceptions sub-scale is based on similar criteria to that of the CIDI psychosis section
(version 1.1), the favored instrument in similar studies [3,17,19,20]. The PERI screening scales,
including the False Beliefs and Perceptions sub-scale, were tested for reliability and criterion va-
lidity, and calibrated against known cases of psychiatric disorders in a pilot research project con-
ducted in Israel [13]. In addition to the ability to discern between psychiatric cases and non-
cases [13], the False Beliefs and Perceptions sub-scale has high internal reliability (α = 0.80 in the
current study and 0.85 in previous studies [21]).
Psychiatric Hospitalisation Case Registry
The National Psychiatric Hospitalization Case Registry [22,23] is a complete listing of all psy-
chiatric hospitalizations in the country, including psychiatric hospitals, day hospitals, and psy-
chiatric units in general hospitals, using ICD discharge diagnoses assigned by a board-certified
psychiatrist. Reporting is regularly monitored to ensure accuracy. A study comparing RDC di-
agnoses with registry diagnoses found that the sensitivity of the registry diagnosis of non-affec-
tive psychotic disorders was 0.89, and of schizophrenia was 0.87 [22,23]. A recent study on this
data set showed that 93% of patients with schizophrenia were hospitalized at some point during
their lifetime [24].
Study Population
Of the 4,914 subjects who participated in the screening interview, 172 had a psychiatric hospi-
talization, 73 (1.6%) of whom were hospitalized at least once with a diagnosis of schizophrenia
either before or after screening. During the follow up, 169 cohort members had died and were
thus excluded from the analysis. In addition, we removed from the analyses subjects 1) diag-
nosed with a psychotic disorder during the SADS-I interview; 2) hospitalized in psychiatric fa-
cilities prior to the PERI assessment; and 3) with missing data on the PERI assessment of
psychiatric symptoms. The final analytic sample included 4,638 subjects (94.4% of the original
sample; see Fig. 1).
During the follow-up period (mean time from PERI interview to first hospitalization or to
date of merger in 2007 was 23.5 years, SD = 3.7), 19 individuals (0.4%) were identified in the
Table 1. Principal component analysis of negative symptoms—item loadings.
Factor 1 Factor 2 Factor 3 Factor 4
Oversleeping 0.61 0.05 −0.04 0.05
Inability to get things done 0.77 0.09 0.04 0.01
Trouble getting things started 0.78 0.11 −0.01 −0.04
Anergia 0.53 0.15 0.08 0.02
Being a loner 0.15 0.52 −0.05 0.02
Being a closed person 0.10 0.78 −0.03 0.01
Rarely visiting or talking to others 0.12 0.79 0.02 0.01
Not making friends easily −0.01 0.67 0.15 0.06
Feeling detached from others 0.37 0.53 0.04 0.03
Unclear speech −0.01 0.06 0.75 −0.03
Repeats words mechanically −0.01 0.01 0.70 −0.02
Poor cleanliness and self-care 0.07 0.03 0.40 0.17
No external expression 0.05 0.04 0.19 0.80
Frozen expression −0.01 0.06 −0.04 0.84
doi:10.1371/journal.pone.0119852.t001
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Psychiatric Hospitalization Case Registry as having been later hospitalized at least once for
schizophrenia. The reason for this relatively low rate of schizophrenia (0.4%) in the analytic
sample is because the peak incidence of schizophrenia is in the decade 15–24 [25]; thus, the
majority of the subjects with this disorder had already manifested their illness at the time of the
epidemiological study, and hence they were excluded from this analysis. Twelve subjects
(0.3%) were identified as having psychotic disorders other than schizophrenia. An additional
81 subjects (1.7%) were identified as having been hospitalized for non-psychotic disorders, in-
cluding drug use, personality disorders, affective disorders, anxiety disorders and organic
mental disorders.
Statistical Analysis
All analyses were performed using the software package Stata, version 10 [26]. The data were
weighted to estimate the rates of negative symptoms in the original population from which the
cohort sample was drawn. This was done using Stata’s tools for complex survey data analysis
which incorporates the survey design characteristics (weighting, clustering, and stratification)
into the data analysis to provide accurate point estimates and standard errors [27]. All numbers
shown represent the actual number of subjects, whereas the percentages are weighted.
Fig 1. Study population.
doi:10.1371/journal.pone.0119852.g001
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As the PERI was not designed to assess negative symptoms, we tested the construct validity
of the negative symptoms identified by comparing the prevalence of these symptoms between
people who were diagnosed with schizophrenia at the initial assessment in the epidemiological
study in the 1980's (n = 24), those diagnosed with other definite RDC mental disorders (n =
1,624) and the rest of the sample.
First, in order to assess the effect of baseline reports of negative symptom on later hospitali-
zation for schizophrenia, with no assumptions regarding the relative importance of the fre-
quency at which the symptom was endorsed, we created for each subject a mean negative
symptom score of the 9 self-report items (rated 0–4). This mean score was then used in a logis-
tic regression model to predict later hospitalization for schizophrenia.
Next, for purposes of analysis, each self-report item was dichotomized as present (indicating
a score of 4) or absent (indicating a score of 0–3), similar to the coding of the interviewer-rated
items. We then examined the prevalence of negative symptoms in the population, as well as the
prevalence of negative symptom clusters (avolition, social withdrawal, speech deficit, flat affect
and poor hygiene). Next, a logistic regression analysis examining the presence of any negative
symptom and risk of later hospitalization for schizophrenia was performed. To examine the
specificity of negative symptoms as predictors of schizophrenia, risk of hospitalization for non-
psychotic disorders was also tested. For all logistic regression models, the reference group was
people who did not report any negative symptoms. Associations were expressed as odds ratios
and 95% confidence intervals (95% CI).
Finally, we divided those with negative symptoms into sub-groups based on the co-occur-
rence of psychotic experiences (i.e, negative symptoms alone or negative symptoms and psy-
chotic experiences together). We then estimated the interaction between psychotic experiences
(coded as absent / weak / strong) and negative symptoms (coded as absent / present) in the
model predicting hospitalization for schizophrenia, comparing multiplicative effect sizes (odds
ratios) using the Stata test command.
Results
Construct validity of negative symptom scale
The construct validity of the negative symptom scale was examined by comparing the preva-
lence of these 14 symptoms between 24 subjects diagnosed with schizophrenia at the initial as-
sessment in the epidemiological study, those diagnosed with other definite RDC mental
disorders and the rest of the sample. As can be seen in Table 2, the majority of the PERI items
hypothesized to reflect negative symptoms were more prevalent among people diagnosed with
schizophrenia. The distinction between subjects with schizophrenia and the general population
was non-significant for three items: “rarely visiting or talking to others”, “not making friends
easily”; and interviewer rating of “frozen expression”. Of the 14 symptoms assessed, six were
significantly more prevalent in subjects with schizophrenia than in subjects with other mental
disorders and 2 additional items showed a trend in the same direction. The prevalence of “rare-
ly visiting or talking to others” was numerically higher among subjects with other mental disor-
ders than among subjects with schizophrenia, though both groups differed significantly from
the general population.
Prevalence of negative symptoms and association with baseline
demographics and some clinical characteristics
The weighted mean age of the sample in 2007 was 53.7 years (SD = 2.8), 50% were male. After
removing subjects with diagnosable psychotic disorders at baseline, 20.2% (n = 1,054) had at
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least one negative symptom. Of these, 1.6% (n = 9) were later hospitalized for schizophrenia,
0.1% (n = 1) were hospitalized for psychotic disorders other than schizophrenia, and 3.4%
(n = 38) were hospitalized for other psychiatric disorders. A closer inspection of the symptom
clusters suggests that 8.3% of the respondents endorsed symptoms of social withdrawal, 6.5%
avolition, 5.7% flat affect, 2.8% poor hygiene and 1.7% exhibited speech deficits.
Table 3 shows that negative symptoms (one or more) were more prevalent among males,
subjects from North African origin, and those who were unmarried, unemployed and with
fewer years of education. Similarly, the prevalence of negative symptoms was higher among
cannabis users and participants with poorer social functioning. The prevalence of negative
symptoms was 1.5 times higher among those with positive psychotic experiences compared to
those without psychotic experiences (Table 3).
Prediction of hospitalization for schizophrenia (ICD-10 F20.0-F20.9)
To assess the effect of self-report negative symptoms on later hospitalization for schizophrenia,
with no assumptions regarding the way in which negative symptoms should be modeled, we
examined the association using the mean negative symptom scores. Higher negative symptom
scores significantly increased the risk of later hospitalization for schizophrenia (OR = 2.80,
95% CI: 1.67–4.68), indicating that with every unit increase in the mean negative symptom
score there was almost a three-fold increase in risk of later hospitalization for schizophrenia.
Table 2. Construct validity of negative symptoms—comparison of prevalence (χ2) between people with a RDC diagnosis of schizophrenia or
other mental disorders and the general population*.










Self-reported Oversleeping 1.6% 6.8% 45.7% <.001 <.001
Inability to get things
done
0.4% 2.9% 6.8% <.001 .23
Trouble getting things
started
0.3% 3.6% 54.1% <.001 <.001
Anergia 0.9% 2.1% 13.7% <.001 .001
Being a loner 0.6% 3.4% 11.3% <.001 .07
Being a closed person 0.5% 3.7% 8.6% <.001 .24
Rarely visiting or
talking to others
0.9% 5.5% 3.1% .12 .45
Not making friends
easily
2.8% 4.3% 3.1% .90 .68
Feeling detached
from others
0.3% 1.7% 7.4% <.001 .04
Interviewer-
rated
Unclear speech 0.7% 2.4% 4.7% .01 .42
Repeats words
mechanically
0.6% 0.7% 10.3% <.001 <.001
No external
expression
3.1% 4.4% 12.5% .01 .07
Frozen expression 2.7% 3.0% 4.9% .48 .54
Poor cleanliness and
self-care
2.3% 4.0% 30.0% <.001 <.001
* Numbers in the table represent the actual number of subjects; percentages represent weighted % among each diagnostic group (column)
doi:10.1371/journal.pone.0119852.t002
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Overall, when examining all 14 dichotomized negative symptoms, the presence of any nega-
tive symptom was associated with increased risk for later hospitalization with an ICD-10 diag-
nosis of schizophrenia (OR = 9.0, 95% CI: 2.6–30.4). However, when examining the interaction
between psychotic experiences and negative symptoms on risk of hospitalization for schizo-
phrenia (Table 4), the significant increase in risk was limited only to the co-occurrence of both
strong positive psychotic experiences and negative symptoms; here the risk for later schizo-
phrenia was greatest, at OR = 13.0 (95% CI: 2.1–79.4). The results of the interaction analyses
indicate that a trend towards significance was observed for both weak [F(1, 4544) = 3.03, p =
.08] and strong psychotic experiences [F(1, 4544) = 2.66, p = .10]. Results of classic regression
models including main effects and interaction terms yielded similar results (negative symptoms
and weak psychotic experiences: OR = 14.7, p = .08; negative symptoms and strong psychotic
experiences: OR = 11.3, p = .10). While these analyses were underpowered to detect significant
Table 3. The prevalence of at least one negative symptoms by demographic and clinical characteristics (χ2)*.
Prevalence of negative symptoms P-value
Sex Male 572 (23.5%) <.001
Female 482 (17.0%)
Ethnicity European 377 (15.8%) <.001
North African 677 (29.5%)
Marital status Married 708 (17.9%) <.001
Unmarried 346 (31.8%)
Education <12 590 (34.2%) <.001
> = 12 459 (14.2%)
Employment Employed 940 (19.5%) <.001
Unemployed 114 (32.2%)
Cannabis use No 852 (19.1%) <.001
Yes 202 (27.9%)
Social functioning Good-superior 448 (20.8%) <.001
Poor-fair 208 (46.0%)
Positive psychotic experiences (weak or strong) Absent 205 (15.1%) <.001
Present 849 (22.3%)
* Numbers in the table represent the actual number of subjects; percentages represent the weighted % among each level of the variable examined (row).
doi:10.1371/journal.pone.0119852.t003





Risk for schizophrenia hospitalizationOR
(95% CI)
None 985 (99.8%) 3 (0.02%) 1
Weak psychotic experiences 2,106 (99.9%) 4 (0.01%) 0.6 (0.1–3.3)
Strong psychotic experiences 431 (99.7%) 3 (0.03%) 1.5 (0.3–8.1)
Negative symptoms 198 (99.8%) 1 (0.02%) 0.8 (0.1–8.0)
Weak psychotic experiences and negative
symptoms
478 (98.4%) 3 (1.6%) 7.0 (0.9–52.6)
Strong psychotic experiences and
negative symptoms
328 (97.1%) 5 (2.9%) 13.0 (2.1–79.4)
* Numbers in the table represent the actual number of subjects; percentages represent the weighted % among each symptom group (row)
doi:10.1371/journal.pone.0119852.t004
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differences, the results suggest that risk of hospitalization for schizophrenia given both psy-
chotic experiences (weak or strong) and negative symptoms was greater than the sum of the
risks for schizophrenia given psychotic experiences or negative symptoms alone.
Prediction of hospitalization for other, non-psychotic psychiatric
disorders
Higher mean negative symptom scores significantly increased the risk of later hospitalization
for non-psychotic disorders (OR = 1.74, 95% CI: 1.09–2.77), though to a lesser degree than risk
for schizophrenia. Similarly, the presence of any negative symptom was associated with in-
creased risk of hospitalization for other, non-psychotic psychiatric disorders, though to a lesser
degree (OR = 3.5, 95% CI: 2.0–6.0). No interaction was found between negative symptoms and
weak [F(1, 4606) = 1.49, p = .23] or strong psychotic experiences [F(1, 4606) = 1.87, p = .17] on
risk of hospitalization for non-psychotic disorders.
Discussion
Similar to psychotic experiences, negative symptoms are common in the general population.
The prevalence found in this study is similar to that reported in a population-based study in
Germany and in a study of American college students [28], finding that between 20–22% of the
general population had one or more negative symptoms. While negative symptoms are com-
mon in the general population, the vast majority of people with negative symptoms do not
manifest a clinically diagnosed psychiatric disorder. This report adds to the existing literature
as it is the first to examine the association between negative symptoms in the general popula-
tion and hospital diagnoses of schizophrenia in a population-based sample, is based on a birth
cohort and has the longest duration of follow-up.
Negative symptoms were more prevalent among males, subjects from North African origin,
and those who were unmarried, unemployed and with fewer years of education. The prevalence
of negative symptoms was higher among cannabis users and participants with poorer social
functioning. This indicates that negative symptoms share some demographic patterns and risk
factors with schizophrenia [29,30].
Overall, negative symptoms appeared to be associated with both later schizophrenia and, to
a lesser degree, non-psychotic disorders. However, when examining the interaction between
psychotic experiences and negative symptoms, the findings indicated that neither negative
symptoms nor psychotic experiences alone predicted later schizophrenia. It was only the com-
bined presence of both strong positive psychotic experiences and negative symptoms together
that showed a statistically significant risk for later schizophrenia. Although the data in this re-
port cannot speak to this possibility, it supports the notion presented by Moller [31] that in the
prodromal phase of the illness, negative symptoms begin worsening with the emergence of pos-
itive symptoms, leading to the initial acute psychotic episode. This was later confirmed in a lon-
gitudinal study on the topic reporting that transition from psychotic experiences to psychotic
disorder is contingent on the earlier presence of negative symptoms [8].
Limitations
The assessment of negative symptoms in this study was done using items that were not de-
signed as a scale for the assessment of negative symptoms, and were not previously validated
for this purpose. However, the present data analysis suggests that the symptoms examined
were all more prevalent in people with schizophrenia, hence supporting the construct validity
of most of these items. Additionally, not all negative symptoms were evaluated. For example,
anhedonia or lack of emotional experience was not assessed as part of the epidemiological
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survey. Another potential limitation is that 9 of the 14 negative symptoms were based on self-
report rather than on clinical observations.
The diagnoses of schizophrenia were drawn from a psychiatric hospitalization registry. Reg-
istry diagnoses are clinical, not research, diagnoses. However, they are assigned by board-certi-
fied psychiatrists who had the benefit of observing the patients throughout one or more
hospitalizations and had been trained in the use of the diagnostic criteria of the ICD-10 and
DSM-IV. Studies that compared clinical diagnoses of schizophrenia assigned in state hospitals
with research diagnoses have shown a high degree of concordance [32], and a previous study
by our group comparing registry diagnoses to RDC diagnoses found that the sensitivity of the
registry diagnosis of non-affective psychotic disorders is 0.89, and of schizophrenia 0.87 [22].
We are also limited by lack of data regarding emigrants. However, recent studies on schizo-
phrenia and emigration argue against the possibility that patients more prone to schizophrenia
are more likely to emigrate compared to those less prone to schizophrenia [33].
Finally, after removing subjects with diagnosable psychotic disorders at baseline, only 19
people with schizophrenia, the main outcome of interest, were included in the analytic sample.
Hence, the regression models may be underpowered, resulting in large confidence intervals.
For this reason, the inclusion of potential covariates in the models was not possible. As people
whose psychotic illness had manifested prior to the baseline assessment (ages 25–34) were
removed from the analyses, and as the peak incidence for males and females is in the decade
15–24 [25], the remaining participants are characterized by a later age of onset, which may
limit the generalizability of these findings.
Supporting Information
S1 Table. Assessment of negative symptoms.
(DOCX)
Acknowledgments
We thank Dr. Itzhak Levav for his role in collecting the epidemiological data in the 1980's and
for his contribution to this paper.
Author Contributions
Conceived and designed the experiments: MWMD. Analyzed the data: MWNW JvO. Con-
tributed reagents/materials/analysis tools: IL BPD ZH RY. Wrote the paper: MWNW JvOMD
IL BPD.
References
1. Linscott RJ, van Os J. An updated and conservative systematic review and meta-analysis of epidemio-
logical evidence on psychotic experiences in children and adults: on the pathway from proneness to
persistence to dimensional expression across mental disorders. Psychol Med. 2013; 43: 1133–1149.
doi: 10.1017/S0033291712001626 PMID: 22850401
2. Dominguez M, Wichers M, Lieb R, Wittchen HU, van Os J. Evidence that onset of clinical psychosis is
the outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort
study. Schizophrenia bulletin. 2011; 37: 84–93. doi: 10.1093/schbul/sbp022 PMID: 19460881
3. Hanssen M, Bak M, Bijl R, VolleberghW, van Os J. The incidence and outcome of subclinical psychotic
experiences in the general population. Br J Clin Psychol. 2005; 44: 181–191. PMID: 16004653
4. Kaymaz N, Drukker M, Lieb R, Wittchen HU, Werbeloff N, Weiser M, et al. Do subthreshold psychotic
experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A
systematic review and meta-analysis, enriched with new results. Psychological Medicine. 2012; 42:
2239–2253. doi: 10.1017/S0033291711002911 PMID: 22260930
Negative Symptoms and Schizophrenia
PLOS ONE | DOI:10.1371/journal.pone.0119852 March 6, 2015 10 / 12
5. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H. Children's self-reported psychotic
symptoms and adult schizophreniform disorder: A 15-year longitudinal study. Arch Gen Psychiatry.
2000; 57: 1053–1058. PMID: 11074871
6. Werbeloff N, Drukker M, Dohrenwend BP, Levav I, Yoffe R, van Os J, et al. Self-reported attenuated
psychotic symptoms as forerunners of severe mental disorders later in life. Arch Gen Psychiatry. 2012;
69: 467–475. doi: 10.1001/archgenpsychiatry.2011.1580 PMID: 22213772
7. Alphs L, Morlock R, Coon C, Cazorla P, Szegedi A, Panagides J. Validation of a 4-item Negative Symp-
tom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in
schizophrenia. Int J Methods Psychiatr Res. 2011; 20: e31–37. doi: 10.1002/mpr.339 PMID: 21538654
8. Dominguez MD, Saka MC, Lieb R, Wittchen HU, van Os J. Early expression of negative/disorganized
symptoms predicting psychotic experiences and subsequent clinical psychosis: a 10-year study. Am J
Psychiatry. 2010; 167: 1075–1082. doi: 10.1176/appi.ajp.2010.09060883 PMID: 20634371
9. Dohrenwend BP, Levav I, Shrout PE, Schwartz S, Naveh G, Link BG, et al. Socioeconomic status and
psychiatric disorders: the causation-selection issue. Science. 1992; 255: 946–952. PMID: 1546291
10. Levav I, Kohn R, Dohrenwend BP, Shrout PE, Skodol AE, Schwartz S, et al. An epidemiological study
of mental disorders in a 10-year cohort of young adults in Israel. Psychol Med. 1993; 23: 691–707.
PMID: 8234576
11. Dohrenwend BP. 'The problem of validity in field studies of psychological disorders' revisited. Psychol
Med. 1990; 20: 195–208. PMID: 2181517
12. Dohrenwend BP, Shrout PE, Egri G, Mendelsohn FS. Nonspecific psychological distress and other di-
mensions of psychopathology. Measures for use in the general population. Arch Gen Psychiatry. 1980;
37: 1229–1236. PMID: 7436685
13. Shrout PE, Dohrenwend BP, Levav I. A discriminant rule for screening cases of diverse diagnostic
types: preliminary results. J Consult Clin Psychol. 1986; 54: 314–319. PMID: 3487562
14. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia.
Arch Gen Psychiatry. 1978; 35: 837–844. PMID: 678037
15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia.
Schizophr Bull. 1987; 13: 261–276. PMID: 3616518
16. Andreasen NC Scale for the assesment of negative symptoms: SANS. Lowa: the University of Lowa;
1981.
17. Hanssen MS, Bijl RV, VolleberghW, van Os J. Self-reported psychotic experiences in the general pop-
ulation: a valid screening tool for DSM-III-R psychotic disorders? Acta Psychiatr Scand. 2003; 107:
369–377. PMID: 12752033
18. Welham J, Scott J, Williams G, Najman J, Bor W, O'CallaghanM, et al. Emotional and behavioural ante-
cedents of young adults who screen positive for non-affective psychosis: a 21-year birth cohort study.
Psychol Med. 2008: 1–10.
19. Cougnard A, Marcelis M, Myin-Germeys I, De Graaf R, VolleberghW, Krabbendam L, et al. Does nor-
mal developmental expression of psychosis combine with environmental risk to cause persistence of
psychosis? A psychosis proneness-persistence model. Psychol Med. 2007; 37: 513–527. PMID:
17288646
20. van Os J, Hanssen M, Bijl RV, VolleberghW. Prevalence of psychotic disorder and community level of
psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry. 2001; 58: 663–668. PMID:
11448373
21. Whaley AL. Ethnicity/race, paranoia, and psychiatric diagnoses: Clinician bias versus sociocultural dif-
ferences. Journal of Psychopathology and Behavioral Assessment. 1997; 19: 1–20.
22. Weiser M, Kanyas K, Malaspina D, Harvey PD, Glick I, Goetz D, et al. Sensitivity of ICD-10 diagnosis of
psychotic disorders in the Israeli National Hospitalization Registry compared with RDC diagnoses
based on SADS-L. Compr Psychiatry. 2005; 46: 38–42. PMID: 15714193
23. Levav I, Grinshpoon A. Mental health services in Israel. International Psychiatry. 2004; 4: 10–14.
24. Weiser M, Werbeloff N, Dohrenwend BP, Levav I, Yoffe R, Davidson M. Do psychiatric registries in-
clude all persons with schizophrenia in the general population? A population-based longitudinal study.
Schizophr Res. 2012; 135: 187–191. doi: 10.1016/j.schres.2011.12.023 PMID: 22260965
25. Messias EL, Chen CY, EatonWW. Epidemiology of schizophrenia: review of findings and myths. Psy-
chiatr Clin North Am. 2007; 30: 323–338. PMID: 17720026
26. StataCorp STATA Statistical Software: Release 10.1. Texas: College Station; 2008.
27. Scheaffer RL, Mendenhall W, Ott RL, G. GK Elementary Survey Sampling. Boston: Brooks/Cole;
2012.
Negative Symptoms and Schizophrenia
PLOS ONE | DOI:10.1371/journal.pone.0119852 March 6, 2015 11 / 12
28. Barrantes-Vidal N, Lewandowski KE, Kwapil TR. Psychopathology, social adjustment and personality
correlates of schizotypy clusters in a large nonclinical sample. Schizophr Res. 2010; 122: 219–225.
doi: 10.1016/j.schres.2010.01.006 PMID: 20138738
29. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual
markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999; 156: 1328–
1335. PMID: 10484941
30. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature. 2010; 468: 203–212. doi:
10.1038/nature09563 PMID: 21068828
31. Moller HJ. Clinical evaluation of negative symptoms in schizophrenia. Eur Psychiatry. 2007; 22: 380–
386. PMID: 17524626
32. Pulver AE, Carpenter WT, Adler L, McGrath J. Accuracy of the diagnoses of affective disorders and
schizophrenia in public hospitals. Am J Psychiatry. 1988; 145: 218–220. PMID: 3341465
33. Selten JP, Cantor-Graae E, Kahn RS. Migration and schizophrenia. Curr Opin Psychiatry. 2007; 20:
111–115. PMID: 17278906
Negative Symptoms and Schizophrenia
PLOS ONE | DOI:10.1371/journal.pone.0119852 March 6, 2015 12 / 12
